Clinical Utility of Biomarkers in Premature Atherosclerosis
Authors: Kampoli, A.-M.; Tousoulis, D.; Papageorgiou, N.; Pallatza, Z.; Vogiatzi, G.; Briasoulis, A.; Androulakis, E.; Toutouzas, C.; Stougianos, P.; Tentolouris, C.; Stefanadis, C.
Source: Current Medicinal Chemistry, Volume 19, Number 16, June 2012 , pp. 2521-2533(13)
Publisher: Bentham Science Publishers
Abstract:Atherosclerosis is a very complex procedure responsible for the development of coronary artery disease which is the leading cause of death in the civilized world. The obvious pandemic character of atherosclerosis augments the need to discover an ideal biomarker, which will be able to facilitate the clinical diagnosis of the atherosclerosis from the physicians especially in the early stages of the atherosclerotic process. Among the biomarkers that are already used there are classical ones, such as c-reactive protein, interleukins, tumour necrosis factor, apolipoproteins, fibrinogen, homocysteine, and novel promising ones such as lipoprotein-associated phospholipase, asymmetric dimethylarginine, myeloperoxidase, cathepsins and cystatin C. The possibility of combining circulating biomarkers with other methods such as non-invasive and invasive imaging is clinically attractive because this could contribute to the improved diagnosis and understanding of premature atherosclerosis pathogenesis.
Document Type: Research Article
Affiliations: Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, Greece.
Publication date: June 1, 2012
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.